

Søgeprotokol for Nationale Kliniske Retningslinjer

Projekttitel/aspekt	NKR for høfeber. Primærlitteratur
Kontakt projektgruppe	Morten Opstrup/Lone Bilde, SST
Kontakt søgespecialist	Jens Peter Andersen/Birgitte Holm Petersen, SST
Senest opdateret	10. Marts 2015

Baggrund	Høfeber og allergisk helårssnue (allergisk rhinoconjunctivitis) er hyppigt forekommende, kroniske sygdomme hos såvel voksne som børn. Hver femte skolebarn og yngre voksne lider af høfeber eller allergisk helårssnue. Forekomsten af høfeber i befolkningen som helhed vurderes at være ca. 15% og forekomsten af allergisk helårssnue ca. 10%. Høfeber er forårsaget af allergi over for pollen, medens allergisk helårssnue skyldes allergi over for husstøvmider, pelsdyr og andre allergener. Sygdommene medfører nedsat livskvalitet og sygefravær, og ledsages yderligere ofte af astma og fødevarerallergi. Udrednings- og behandlingstilbuddet foregår på tværs af sektorer, og er i dag ofte mangelfuldt og præget af geografisk og social variation. Det forventes derfor, at en national klinisk retningslinje på området kan sikre en mere ensartet og fagligt korrekt udredning samt evidensbaseret behandling med henblik på bedre symptomkontrol, patienttilfredshed og bedre langtidsprognose.
Inklusions- og eksklusionskriterier	Sprog: Engelsk, dansk, norsk og svensk År: de sidste 10 år, (2003-2014) Population: Alle Publikationstyper: RCT

Informationskilder

Databaser	Interface	Dato for søgning
Embase	OID	03-12-2014 - 22-01-2015
Medline	OID	03-12-2014 - 22-01-2015

Note

- Søgetermer og inklusions- og eksklusionskriterier er tilpasset de enkelte databaser.
- Dubletter er så vidt muligt frasorteret ved hjælp af RefWorks. De fundne referencer overføres til Covidence (referenceværktøj)
- Fuldttekster præsenteres i Covidence i pdf-format
- Søgestrategi for hver enkelt database præsenteres – hvis muligt vises det eksplicit hvor mange referencer den enkelte søgestreng genererer

Søgestrategi

Embase

PICO 1

ID	Søgeterm	Hits
1	allergic rhinitis/	20631
2	Allergic rhinitis.mp.	26467
3	Allergic rhinoconjunctivis.mp.	1
4	rhinoconjunctivitis/	3227
5	hay fever/	9178
6	Hay fever.mp.	9919
7	Hayfever.mp.	439
8	Nasal allergy.mp.	1097
9	Nasal allergies.mp.	166
10	nose obstruction/	8273
11	Nasal congestion.mp.	2307
12	nose congestion.mp.	5158
13	congested nose.mp.	23
14	nose obstruction.mp.	8291
15	nasal obstruction.mp.	5431
16	nasal pruritus/	706
17	nasal pruritus.mp.	739
18	Nasal itch*.mp.	398
19	itchy nose*.mp.	205
20	rhinorrhea/	6498
21	Rhinorrhea.mp.	9773
22	or/1-21	55262
23	exp antihistaminic agent/	172627
24	Antihistamine.mp.	5844
25	exp histamine H1 receptor antagonist/	100182
26	Acrivastin*.mp,tn.	484
27	Histamin* H1 antagonist*.mp.	388
28	Bilastin*.mp,tn.	115
29	Cetirizin*.mp,tn.	6130
30	Desloratadin*.mp,tn.	1829
31	Ebastin*.mp,tn.	990
32	Fexofanadin*.mp,tn.	0
33	Levocetirizin*.mp,tn.	1276
34	Loratadin*.mp,tn.	5044
35	or/23-34	173364
36	Nasal steroid*.mp,tn.	551
37	Nasal glucocorticoid*.mp,tn.	39

38	Beclomethason*.mp,tn.	3465
39	Budesonid*.mp,tn.	16786
40	Fluticason*.mp,tn.	13145
41	Momethason*.mp,tn.	24
42	Triamcinolon*.mp,tn.	24285
43	Ciclesonid*.mp,tn.	1129
44	or/36-43	49977
45	22 and 35 and 44	1583
46	Clinical trial/	838297
47	Randomized controlled trial/	355617
48	Randomization/	63900
49	Single blind procedure/	19033
50	Double blind procedure/	118503
51	Crossover procedure/	40609
52	Placebo/	259915
53	randomi?ed controlled trial\$.tw.	105688
54	Rct.tw.	15313
55	Random allocation.tw.	1385
56	Randomly allocated.tw.	21348
57	Allocated randomly.tw.	1982
58	(allocated adj2 random).tw.	798
59	Single blind\$.tw.	15153
60	Double blind\$.tw.	151211
61	((treble or triple) adj blind\$.tw.	429
62	Placebo\$.tw.	209692
63	Prospective study/	266696
64	or/46-63	1415665
65	Case study/	28994
66	Case report.tw.	277134
67	Abstract report/ or letter/	923345
68	or/65-67	1223558
69	64 not 68	1377012
70	Clinical study/	106319
71	Case control study/	82777
72	Family study/	10559
73	Longitudinal study/	70738
74	Retrospective study/	366910
75	Prospective study/	266696
76	Randomized controlled trials/	60811
77	75 not 76	264997
78	Cohort analysis/	182266
79	(Cohort adj (study or studies)).mp.	125662
80	(Case control adj (study or studies)).tw.	78589
81	(follow up adj (study or studies)).tw.	46990

82	(observational adj (study or studies)).tw.	69440
83	(epidemiologic\$ adj (study or studies)).tw.	76439
84	(cross sectional adj (study or studies)).tw.	92033
85	or/70-74,77-84	1271879
86	45 and (or/69,85)	801
87	limit 86 to (danish or english or swedish or norwegian)	753
88	limit 87 to yr="2009 -Current"	259

PICO 2

ID	Søgeterm	Hits
1	rhinoconjunctivitis/	3227
2	exp allergic conjunctivitis/	4188
3	Allergic rhinoconjunctivitis.mp.	1329
4	conjunctivitis.mp.	22131
5	hay fever/	9178
6	Hay fever.mp.	9919
7	Hayfever.mp.	439
8	Ocular allerg*.mp.	698
9	or/1-8	34448
10	Antazolin*.mp,tn.	836
11	Azelastin*.mp,tn.	2141
12	Emedastin*.mp,tn.	347
13	Ketotifen*.mp,tn.	4504
14	Levocabastin*.mp,tn.	999
15	Olopatadin*.mp,tn.	882
16	or/10-15	8063
17	exp antihistaminic agent/	172627
18	Antihistamine.mp.	5844
19	exp histamine H1 receptor antagonist/	100182
20	Acrivastin*.mp,tn.	484
21	Histamin* H1 antagonist*.mp.	388
22	Bilastin*.mp,tn.	115
23	Cetirizin*.mp,tn.	6130
24	Desloratadin*.mp,tn.	1829
25	Ebastin*.mp,tn.	990
26	Fexofanadin*.mp,tn.	0
27	Levocetirizin*.mp,tn.	1276
28	Loratadin*.mp,tn.	5044
29	or/17-28	173364
30	9 and 16 and 29	1300
31	Clinical trial/	838297
32	Randomized controlled trial/	355617
33	Randomization/	63900

34	Single blind procedure/	19033
35	Double blind procedure/	118503
36	Crossover procedure/	40609
37	Placebo/	259915
38	randomi?ed controlled trial\$.tw.	105688
39	Rct.tw.	15313
40	Random allocation.tw.	1385
41	Randomly allocated.tw.	21348
42	Allocated randomly.tw.	1982
43	(allocated adj2 random).tw.	798
44	Single blind\$.tw.	15153
45	Double blind\$.tw.	151211
46	((treble or triple) adj blind\$.tw.	429
47	Placebo\$.tw.	209692
48	Prospective study/	266696
49	or/31-48	1415665
50	Case study/	28994
51	Case report.tw.	277134
52	Abstract report/ or letter/	923345
53	or/50-52	1223558
54	49 not 53	1377012
55	Clinical study/	106319
56	Case control study/	82777
57	Family study/	10559
58	Longitudinal study/	70738
59	Retrospective study/	366910
60	Prospective study/	266696
61	Randomized controlled trials/	60811
62	60 not 61	264997
63	Cohort analysis/	182266
64	(Cohort adj (study or studies)).mp.	125662
65	(Case control adj (study or studies)).tw.	78589
66	(follow up adj (study or studies)).tw.	46990
67	(observational adj (study or studies)).tw.	69440
68	(epidemiologic\$ adj (study or studies)).tw.	76439
69	(cross sectional adj (study or studies)).tw.	92033
70	or/55-59,62-69	1271879
71	30 and (or/54,70)	632
72	limit 71 to (danish or english or swedish or norwegian)	565
73	limit 72 to yr="2003 -Current"	397

PICO 3

ID	Søgeterm	Hits
1	allergic rhinitis/	20781
2	Allergic rhinitis.mp.	26639
3	Allergic rhinoconjunctivitis.mp.	1
4	rhinoconjunctivitis/	3255
5	hay fever/	9221
6	Hay fever.mp.	9964
7	Hayfever.mp.	440
8	Nasal allergy.mp.	1097
9	Nasal allergies.mp.	166
10	nose obstruction/	8386
11	Nasal congestion.mp.	2331
12	nose congestion.mp.	5192
13	congested nose.mp.	23
14	nose obstruction.mp.	8404
15	nasal obstruction.mp.	5475
16	nasal pruritus/	715
17	nasal pruritus.mp.	748
18	Nasal itch*.mp.	400
19	itchy nose*.mp.	205
20	rhinorrhea/	6585
21	Rhinorrhea.mp.	9909
22	or/1-21	55720
23	exp leukotriene receptor blocking agent/	15350
24	Antileukotrien*.mp.	546
25	Leukotrien*.mp.	31369
26	Montelukast.mp.	6936
27	exp montelukast/	6817
28	or/23-27	36757
29	exp antihistaminic agent/	173683
30	Antihistamine.mp.	5874
31	exp histamine H1 receptor antagonist/	100686
32	Acrivastin*.mp,tn.	487
33	Histamin* H1 antagonist*.mp.	391
34	Bilastin*.mp,tn.	120
35	Cetirizin*.mp,tn.	6193
36	Desloratadin*.mp,tn.	1856
37	Ebastin*.mp,tn.	1003
38	Fexofanadin*.mp,tn.	0
39	Levocetirizin*.mp,tn.	1300
40	Loratadin*.mp,tn.	5098
41	or/29-40	174422

42	22 and 28 and 41	1441
43	Clinical trial/	841600
44	Randomized controlled trial/	358165
45	Randomization/	64181
46	Single blind procedure/	19230
47	Double blind procedure/	119287
48	Crossover procedure/	40987
49	Placebo/	262552
50	randomi?ed controlled trial\$.tw.	107087
51	Rct.tw.	15521
52	Random allocation.tw.	1397
53	Randomly allocated.tw.	21509
54	Allocated randomly.tw.	1992
55	(allocated adj2 random).tw.	801
56	Single blind\$.tw.	15287
57	Double blind\$.tw.	152315
58	((treble or triple) adj blind\$.tw.	435
59	Placebo\$.tw.	211434
60	Prospective study/	270149
61	or/43-60	1426829
62	Case study/	29541
63	Case report.tw.	280188
64	Abstract report/ or letter/	928808
65	or/62-64	1232538
66	61 not 65	1387937
67	42 and 66	594
68	limit 67 to (danish or english or swedish or norwegian)	555
69	limit 68 to yr="2007 -Current"	282

PICO 4

ID	Søgeterm	Hits
1	allergic rhinitis/	20631
2	Allergic rhinitis.mp.	26467
3	Allergic rhinoconjunctivis.mp.	1
4	rhinoconjunctivitis/	3227
5	hay fever/	9178
6	Hay fever.mp.	9919
7	Hayfever.mp.	439
8	Nasal allergy.mp.	1097
9	Nasal allergies.mp.	166
10	nose obstruction/	8273
11	Nasal congestion.mp.	2307
12	nose congestion.mp.	5158
13	congested nose.mp.	23
14	nose obstruction.mp.	8291
15	nasal obstruction.mp.	5431
16	nasal pruritus/	706
17	nasal pruritus.mp.	739
18	Nasal itch*.mp.	398
19	itchy nose*.mp.	205
20	rhinorrhea/	6498
21	Rhinorrhea.mp.	9773
22	or/1-21	55262
23	exp steroid/	1188562
24	Steroid*.mp.	328378
25	exp corticosteroid/	737805
26	Corticosteroid*.mp,tn.	245232
27	Glucocorticoid*.mp,tn.	101228
28	Methylprednisolon*.mp,tn.	77343
29	Hydrocortison*.mp,tn.	115393
30	Triamcinolonhexacetonid*.mp,tn.	4
31	or/23-30	1299136
32	intramuscular drug administration/	66185
33	Depot.mp.	12810
34	Intramuscular.mp.	93455
35	Prolonged.mp.	292888
36	Systemic.mp.	474660
37	or/32-36	852125
38	exp antihistaminic agent/	172627
39	Antihistamine.mp.	5844
40	exp histamine H1 receptor antagonist/	100182
41	Acrivastin*.mp,tn.	484

42	Histamin* H1 antagonist*.mp.	388
43	Bilastin*.mp,tn.	115
44	Cetirizin*.mp,tn.	6130
45	Desloratadin*.mp,tn.	1829
46	Ebastin*.mp,tn.	990
47	Fexofanadin*.mp,tn.	0
48	Levocetirizin*.mp,tn.	1276
49	Loratadin*.mp,tn.	5044
50	or/38-49	173364
51	Nasal steroid*.mp,tn.	551
52	Nasal glucocorticoid*.mp,tn.	39
53	Beclomethason*.mp,tn.	3465
54	Budesonid*.mp,tn.	16786
55	Fluticason*.mp,tn.	13145
56	Momethason*.mp,tn.	24
57	Triamcinolon*.mp,tn.	24285
58	Ciclesonid*.mp,tn.	1129
59	or/51-58	49977
60	and/22,31,37,50,59	231
61	Clinical trial/	838297
62	Randomized controlled trial/	355617
63	Randomization/	63900
64	Single blind procedure/	19033
65	Double blind procedure/	118503
66	Crossover procedure/	40609
67	Placebo/	259915
68	randomi?ed controlled trial\$.tw.	105688
69	Ret.tw.	15313
70	Random allocation.tw.	1385
71	Randomly allocated.tw.	21348
72	Allocated randomly.tw.	1982
73	(allocated adj2 random).tw.	798
74	Single blind\$.tw.	15153
75	Double blind\$.tw.	151211
76	((treble or triple) adj blind\$).tw.	429
77	Placebo\$.tw.	209692
78	Prospective study/	266696
79	or/61-78	1415665
80	Case study/	28994
81	Case report.tw.	277134
82	Abstract report/ or letter/	923345
83	or/80-82	1223558
84	79 not 83	1377012
85	Clinical study/	106319

86	Case control study/	82777
87	Family study/	10559
88	Longitudinal study/	70738
89	Retrospective study/	366910
90	Prospective study/	266696
91	Randomized controlled trials/	60811
92	90 not 91	264997
93	Cohort analysis/	182266
94	(Cohort adj (study or studies)).mp.	125662
95	(Case control adj (study or studies)).tw.	78589
96	(follow up adj (study or studies)).tw.	46990
97	(observational adj (study or studies)).tw.	69440
98	(epidemiologic\$ adj (study or studies)).tw.	76439
99	(cross sectional adj (study or studies)).tw.	92033
100	or/85-89,92-99	1271879
101	60 and (or/84,100)	141
102	limit 101 to (danish or english or swedish or norwegian)	132
103	limit 102 to yr="2003 -Current"	99

PICO 5

ID	Søgeterm	Hits
1	allergic rhinitis/	20631
2	Allergic rhinitis.mp.	26467
3	Allergic rhinoconjunctivitis.mp.	1
4	rhinoconjunctivitis/	3227
5	hay fever/	9178
6	Hay fever.mp.	9919
7	Hayfever.mp.	439
8	Nasal allergy.mp.	1097
9	Nasal allergies.mp.	166
10	nose obstruction/	8273
11	Nasal congestion.mp.	2307
12	nose congestion.mp.	5158
13	congested nose.mp.	23
14	nose obstruction.mp.	8291
15	nasal obstruction.mp.	5431
16	nasal pruritus/	706
17	nasal pruritus.mp.	739
18	Nasal itch*.mp.	398
19	itchy nose*.mp.	205
20	rhinorrhea/	6498
21	Rhinorrhea.mp.	9773
22	or/1-21	55262

23	exp steroid/	1188562
24	Steroid*.mp.	328378
25	exp corticosteroid/	737805
26	Corticosteroid*.mp,tn.	245232
27	Glucocorticoid*.mp,tn.	101228
28	Dexamethason*.mp,tn.	123284
29	Prednison*.mp,tn.	140504
30	Prednisolon*.mp,tn.	107264
31	Methylprednisolon*.mp,tn.	77343
32	Hydrocortison*.mp,tn.	115393
33	Triamcinolonhexacetonid*.mp,tn.	4
34	or/23-33	1308032
35	intramuscular drug administration/	66185
36	Depot.mp.	12810
37	Intramuscular.mp.	93455
38	Prolonged.mp.	292888
39	Systemic.mp.	474660
40	or/35-39	852125
41	oral drug administration/	382254
42	oral*.mp.	962807
43	per os.mp.	6053
44	or/41-43	966430
45	and/22,34,40,44	381
46	Clinical trial/	838297
47	Randomized controlled trial/	355617
48	Randomization/	63900
49	Single blind procedure/	19033
50	Double blind procedure/	118503
51	Crossover procedure/	40609
52	Placebo/	259915
53	randomi?ed controlled trial\$.tw.	105688
54	Rct.tw.	15313
55	Random allocation.tw.	1385
56	Randomly allocated.tw.	21348
57	Allocated randomly.tw.	1982
58	(allocated adj2 random).tw.	798
59	Single blind\$.tw.	15153
60	Double blind\$.tw.	151211
61	((treble or triple) adj blind\$).tw.	429
62	Placebo\$.tw.	209692
63	Prospective study/	266696
64	or/46-63	1415665
65	Case study/	28994
66	Case report.tw.	277134

67	Abstract report/ or letter/	923345
68	or/65-67	1223558
69	64 not 68	1377012
70	Clinical study/	106319
71	Case control study/	82777
72	Family study/	10559
73	Longitudinal study/	70738
74	Retrospective study/	366910
75	Prospective study/	266696
76	Randomized controlled trials/	60811
77	75 not 76	264997
78	Cohort analysis/	182266
79	(Cohort adj (study or studies)).mp.	125662
80	(Case control adj (study or studies)).tw.	78589
81	(follow up adj (study or studies)).tw.	46990
82	(observational adj (study or studies)).tw.	69440
83	(epidemiologic\$ adj (study or studies)).tw.	76439
84	(cross sectional adj (study or studies)).tw.	92033
85	or/70-74,77-84	1271879
86	45 and (or/69,85)	161
87	limit 86 to (danish or english or swedish or norwegian)	152
88	limit 87 to yr="2003 -Current"	101

PICO 6+8

ID	Søgeterm	Hits
1	exp pollen/	17874
2	exp pollen allergy/	5517
3	pollen.mp.	30604
4	grass.mp.	22566
5	birch.mp.	5342
6	or/1-5	49244
7	allergic rhinitis/	20781
8	Allergic rhinitis.mp.	26639
9	Allergic rhinoconjunctivis.mp.	1
10	rhinoconjunctivitis/	3255
11	hay fever/	9221
12	Hay fever.mp.	9964
13	Hayfever.mp.	440
14	Nasal allergy.mp.	1097
15	Nasal allergies.mp.	166
16	nose obstruction/	8386
17	Nasal congestion.mp.	2331
18	nose congestion.mp.	5192

19	congested nose.mp.	23
20	nose obstruction.mp.	8404
21	nasal obstruction.mp.	5475
22	nasal pruritus/	715
23	nasal pruritus.mp.	748
24	Nasal itch*.mp.	400
25	itchy nose*.mp.	205
26	rhinorrhea/	6585
27	Rhinorrhea.mp.	9909
28	or/7-27	55720
29	exp immunotherapy/	133543
30	Immunotherapy.mp.	109311
31	Desensiti*.mp.	36253
32	Hyposensiti*.mp.	2535
33	or/29-32	184425
34	and/6,28,33	2791
35	Clinical trial/	841600
36	Randomized controlled trial/	358165
37	Randomization/	64181
38	Single blind procedure/	19230
39	Double blind procedure/	119287
40	Crossover procedure/	40987
41	Placebo/	262552
42	randomi?ed controlled trial\$.tw.	107087
43	Rct.tw.	15521
44	Random allocation.tw.	1397
45	Randomly allocated.tw.	21509
46	Allocated randomly.tw.	1992
47	(allocated adj2 random).tw.	801
48	Single blind\$.tw.	15287
49	Double blind\$.tw.	152315
50	((treble or triple) adj blind\$).tw.	435
51	Placebo\$.tw.	211434
52	Prospective study/	270149
53	or/35-52	1426829
54	Case study/	29541
55	Case report.tw.	280188
56	Abstract report/ or letter/	928808
57	or/54-56	1232538
58	53 not 57	1387937
59	and/34,58	1160
60	limit 59 to (danish or english or swedish or norwegian)	1062
61	limit 60 to yr="2009 -Current"	535

PICO 7

ID	Søgeterm	Hits
1	allergic rhinitis/	20781
2	Allergic rhinitis.mp.	26639
3	Allergic rhinoconjunctivis.mp.	1
4	rhinoconjunctivitis/	3255
5	hay fever/	9221
6	Hay fever.mp.	9964
7	Hayfever.mp.	440
8	Nasal allergy.mp.	1097
9	Nasal allergies.mp.	166
10	nose obstruction/	8386
11	Nasal congestion.mp.	2331
12	nose congestion.mp.	5192
13	congested nose.mp.	23
14	nose obstruction.mp.	8404
15	nasal obstruction.mp.	5475
16	nasal pruritus/	715
17	nasal pruritus.mp.	748
18	Nasal itch*.mp.	400
19	itchy nose*.mp.	205
20	rhinorrhea/	6585
21	Rhinorrhea.mp.	9909
22	or/1-21	55720
23	exp immunotherapy/	133543
24	Immunotherapy.mp.	109311
25	Desensiti*.mp.	36253
26	Hyposensiti*.mp.	2535
27	or/23-26	184425
28	exp mite/	18594
29	exp mite infestation/	6983
30	house dust allergy/	1739
31	house dust allergen/	4424
32	house dust.mp.	12396
33	mite*.mp.	22714
34	exp dermatophagoides/	7305
35	dermatophagoid*.mp.	8762
36	or/28-35	33060
37	and/22,27,36	1309
38	Clinical trial/	841600
39	Randomized controlled trial/	358165
40	Randomization/	64181
41	Single blind procedure/	19230

42	Double blind procedure/	119287
43	Crossover procedure/	40987
44	Placebo/	262552
45	randomi?ed controlled trial\$.tw.	107087
46	Rct.tw.	15521
47	Random allocation.tw.	1397
48	Randomly allocated.tw.	21509
49	Allocated randomly.tw.	1992
50	(allocated adj2 random).tw.	801
51	Single blind\$.tw.	15287
52	Double blind\$.tw.	152315
53	((treble or triple) adj blind\$).tw.	435
54	Placebo\$.tw.	211434
55	Prospective study/	270149
56	or/38-55	1426829
57	Case study/	29541
58	Case report.tw.	280188
59	Abstract report/ or letter/	928808
60	or/57-59	1232538
61	56 not 60	1387937
62	Clinical study/	107250
63	Case control study/	83580
64	Family study/	10629
65	Longitudinal study/	71496
66	Retrospective study/	371935
67	Prospective study/	270149
68	Randomized controlled trials/	62880
69	67 not 68	268388
70	Cohort analysis/	185233
71	(Cohort adj (study or studies)).mp.	127483
72	(Case control adj (study or studies)).tw.	79423
73	(follow up adj (study or studies)).tw.	47296
74	(observational adj (study or studies)).tw.	70501
75	(epidemiologic\$ adj (study or studies)).tw.	76967
76	(cross sectional adj (study or studies)).tw.	93264
77	or/62-66,69-76	1286804
78	37 and 61	501
79	limit 78 to (danish or english or swedish or norwegian)	448
80	limit 79 to yr="2009 -Current"	233
81	limit 79 to yr="2007-2008"	45

PICO 9.1

ID	Søgeterm	Hits
1	cleaning/	6542
2	Cleaning*.mp.	25192
3	vacuum*.mp.	29067
4	Ventilat*.mp.	222241
5	Chemical*.mp.	1243857
6	Matress*.mp.	41
7	Filter*.mp.	132574
8	Air-filter*.mp.	1000
9	Carpet*.mp.	2607
10	Wash*.mp.	125099
11	or/1-10	1736826
12	allergic rhinitis/	20568
13	Allergic rhinitis.mp.	26394
14	Allergic rhinoconjunctivis.mp.	1
15	rhinoconjunctivitis/	3225
16	hay fever/	9182
17	Hay fever.mp.	9925
18	Hayfever.mp.	437
19	Nasal allergy.mp.	1096
20	Nasal allergies.mp.	166
21	nose obstruction/	8230
22	Nasal congestion.mp.	2300
23	nose congestion.mp.	5192
24	congested nose.mp.	23
25	nose obstruction.mp.	8248
26	nasal obstruction.mp.	5404
27	nasal pruritus/	701
28	nasal pruritus.mp.	734
29	Nasal itch*.mp.	397
30	itchy nose*.mp.	202
31	rhinorrhea/	6488
32	Rhinorrhea.mp.	9761
33	or/12-32	55188
34	exp mite/	18444
35	exp mite infestation/	6925
36	house dust allergy/	1719
37	house dust allergen/	4391
38	house dust.mp.	12287
39	mite*.mp.	22540
40	exp dermatophagoides/	7220
41	dermatophagoid*.mp.	8673

42	or/34-41	32822
43	and/11,33,42	189
44	meta analysis/	84746
45	"meta analysis (topic)"/	16069
46	systemat*.ti,ot,ab. and review.pt.	63360
47	meta analys*.ti,ot,kw.	50994
48	metaanalys*.ti,ot,kw.	1664
49	systematic review*.ti,ot,kw.	47978
50	"cochrane database of systematic reviews".jn.	3780
51	or/44-50	177302
52	and/43,51	8
53	limit 52 to (danish or english or swedish or norwegian)	6
54	limit 53 to yr="2003 -Current"	5

PICO 9.2

ID	Søgeterm	Hits
1	House Dust Allergy/	1732
2	allergic rhinitis/ or perennial rhinitis/	23336
3	exp Rhinitis/	65301
4	rhiniti*.tw.	28765
5	4 or 3	69439
6	allerg*.tw.	203456
7	6 and 5	32903
8	7 or 2	37272
9	allergen/ or house dust allergen/	45046
10	exp blomia/ or exp mite/	18575
11	exp Antigen/	1103606
12	Indoor Air Pollution/	10704
13	Dust Exposure/	3138
14	house dust/	2162
15	Environmental Exposure/	78012
16	environmental factor/	68668
17	(MITE* or DUST* or HDM or PYROGLYPHIDAE or EUROGLYPHUS or DERMATOPHAGOIDES or BLOMIA or NORISEN or PHARMALGEN).tw.	60815
18	primary prevention/	28632
19	exp bed/	8616
20	clothing/	8763
21	building/ or furniture/	9242
22	dust control/	465
23	cleaning/	6576
24	avoidance behavior/	21806
25	insect control/	8308
26	prophylaxis/	72250
27	(MITE* and (Avoid* or PROOF or IMPERMEABLE MARGOSA or MITICIDE or "BENZYL BENZOATE" or BENZYLBenzoate or BIOMAL or MILBIOL or NEEMOL or SPINNRAD or "TN MP 100" or NIMBASAN)).tw.	1067
28	(CEDAR or ACARICID* or ACARACID* or "NEEMOIL" or NEEMOIL or MARGOSA or MITICIDE or "BENZYL BENZOATE" or BENZYLBenzoate or BIOMAL or MILBIOL or NEEMOL or SPINNRAD or "TN MP 100" or NIMBASAN).tw.	4585
29	(DWELLING* or HOUSE* or UPHOLSTER* or PILLOW* or MATTRESS* or BED* or CUSHION* or COVER* or ENCAS* or "SOFT FURNISHING" or "SOFT FURNISHINGS CARPET*" or FLOOR* or CURTAIN*).tw.	649927
30	ACARICIDE/	1023
31	NEEM OIL/	344
32	Perennial Rhinitis/pc [Prevention]	100
33	26 or 24 or 31 or 27 or 20 or 25 or 19 or 21 or 29 or 23 or 18 or 22 or 30 or 28	802761
34	11 or 9 or 17 or 12 or 15 or 14 or 10 or 13 or 16	1298373

35	8 and 34	13659
36	35 or 1	14897
37	33 and 36	3836
38	32 or 37	3909
39	Clinical trial/	841365
40	Randomized controlled trial/	357406
41	Randomization/	64115
42	Single blind procedure/	19165
43	Double blind procedure/	119040
44	Crossover procedure/	40847
45	Placebo/	261843
46	randomi?ed controlled trial\$.tw.	106652
47	Rct.tw.	15461
48	Random allocation.tw.	1390
49	Randomly allocated.tw.	21462
50	Allocated randomly.tw.	1989
51	(allocated adj2 random).tw.	800
52	Single blind\$.tw.	15251
53	Double blind\$.tw.	151981
54	((treble or triple) adj blind\$.tw.	433
55	Placebo\$.tw.	210882
56	Prospective study/	269046
57	or/39-56	1424051
58	Case study/	29437
59	Case report.tw.	279618
60	Abstract report/ or letter/	927363
61	or/58-60	1230435
62	57 not 61	1385229
63	limit 38 to (danish or english or swedish or norwegian)	3230
64	limit 63 to yr="2009 -Current"	1354
65	64 and 62	251

Medline

PICO 1

ID	Søgeterm	Hits
1	rhinitis/	9237
2	rhinitis, allergic, perennial/	7494
3	rhinitis, allergic, seasonal/	12586
4	allergic rhinitis.mp.	12902
5	seasonal rhinitis.mp.	279
6	perennial rhinitis.mp.	516
7	rhinoconjunctivitis.mp.	1723
8	hay fever/	12586
9	Hay fever.mp.	3342
10	Hayfever.mp.	332
11	Nasal allerg*.mp.	1263
12	nasal obstruction/	3805
13	Nasal congestion.mp.	1491
14	nose congestion.mp.	4
15	congested nose.mp.	19
16	nose obstruction.mp.	22
17	nasal obstruction.mp.	6580
18	pruritus/	9083
19	nasal pruritus.mp.	48
20	Nasal itch*.mp.	232
21	itchy nose*.mp.	113
22	Rhinorrhea.mp.	4841
23	or/1-22	50581
24	histamine antagonists/	4879
25	exp histamine H1 antagonists/	32792
26	Antihistamine.mp.	4162
27	Histamin* H1 antagonist*.mp.	15024
28	Acrivastin*.mp.	104
29	Bilastin*.mp.	48
30	Cetirizin*.mp.	1571
31	Desloratadin*.mp.	494
32	Ebastin*.mp.	272
33	Fexofanadin*.mp.	0
34	Levocetirizin*.mp.	313
35	Loratadin*.mp.	1341
36	or/24-35	38680
37	Nasal steroid*.mp.	377
38	Nasal glucocorticoid*.mp.	30
39	Beclomethason*.mp.	3569

40	Budesonid*.mp.	4901
41	Fluticason*.mp.	3549
42	Momethason*.mp.	9
43	Triamcinolon*.mp.	9951
44	Ciclesonid*.mp.	300
45	or/37-44	20566
46	23 and 36 and 45	284
47	Randomized Controlled Trials as Topic/	99741
48	randomized controlled trial/	400708
49	Random Allocation/	84147
50	Double Blind Method/	132583
51	Single Blind Method/	20647
52	clinical trial/	501512
53	clinical trial, phase i.pt.	15355
54	clinical trial, phase ii.pt.	24586
55	clinical trial, phase iii.pt.	10075
56	clinical trial, phase iv.pt.	1037
57	controlled clinical trial.pt.	90738
58	randomized controlled trial.pt.	400708
59	multicenter study.pt.	188835
60	clinical trial.pt.	501512
61	exp Clinical Trials as topic/	294927
62	or/47-61	1091507
63	(clinical adj trial\$).tw.	236170
64	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	137262
65	placebos/	34020
66	placebo\$.tw.	169541
67	randomly allocated.tw.	18317
68	(allocated adj2 random\$).tw.	20993
69	or/63-68	453201
70	62 or 69	1252407
71	case report.tw.	216451
72	letter/	886612
73	historical article/	312834
74	or/71-73	1403683
75	70 not 74	1221156
76	Epidemiologic studies/	6277
77	exp case control studies/	712375
78	exp cohort studies/	1441309
79	Case control.tw.	85453
80	(cohort adj (study or studies)).tw.	100075
81	Cohort analy\$.tw.	4222
82	(Follow up adj (study or studies)).tw.	39447

83	(observational adj (study or studies)).tw.	51101
84	Longitudinal.tw.	156253
85	Retrospective.tw.	300619
86	Cross sectional.tw.	189832
87	Cross-sectional studies/	193365
88	or/76-87	2038085
89	46 and (or/75,88)	201
90	limit 89 to (danish or english or swedish or norwegian)	187
91	limit 90 to yr="2009 -Current"	28

PICO 2

ID	Søgeterm	Hits
1	Allergic rhinoconjunctivitis.mp.	688
2	conjunctivitis/	5476
3	conjunctivitis, allergic/	2776
4	conjunctivitis.mp.	14320
5	hay fever/	12586
6	Hay fever.mp.	3342
7	Hayfever.mp.	332
8	Ocular allerg*.mp.	501
9	or/1-8	27488
10	Antazolin*.mp.	216
11	Azelastin*.mp.	628
12	Emedastin*.mp.	86
13	Ketotifen*.mp.	1534
14	Levocabastin*.mp.	294
15	Olopatadin*.mp.	294
16	or/10-15	2787
17	histamine antagonists/	4879
18	exp histamine H1 antagonists/	32792
19	Antihistamine.mp.	4162
20	Histamin* H1 antagonist*.mp.	15024
21	Acrivastin*.mp.	104
22	Bilastin*.mp.	48
23	Cetirizin*.mp.	1571
24	Desloratadin*.mp.	494
25	Ebastin*.mp.	272
26	Fexofanadin*.mp.	0
27	Levocetirizin*.mp.	313
28	Loratadin*.mp.	1341
29	or/17-28	38680
30	9 and 16 and 29	406
31	Randomized Controlled Trials as Topic/	99741
32	randomized controlled trial/	400708
33	Random Allocation/	84147
34	Double Blind Method/	132583
35	Single Blind Method/	20647
36	clinical trial/	501512
37	clinical trial, phase i.pt.	15355
38	clinical trial, phase ii.pt.	24586
39	clinical trial, phase iii.pt.	10075
40	clinical trial, phase iv.pt.	1037
41	controlled clinical trial.pt.	90738

42	randomized controlled trial.pt.	400708
43	multicenter study.pt.	188835
44	clinical trial.pt.	501512
45	exp Clinical Trials as topic/	294927
46	or/31-45	1091507
47	(clinical adj trial\$).tw.	236170
48	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	137262
49	placebos/	34020
50	placebo\$.tw.	169541
51	randomly allocated.tw.	18317
52	(allocated adj2 random\$).tw.	20993
53	or/47-52	453201
54	46 or 53	1252407
55	case report.tw.	216451
56	letter/	886612
57	historical article/	312834
58	or/55-57	1403683
59	54 not 58	1221156
60	Epidemiologic studies/	6277
61	exp case control studies/	712375
62	exp cohort studies/	1441309
63	Case control.tw.	85453
64	(cohort adj (study or studies)).tw.	100075
65	Cohort analy\$.tw.	4222
66	(Follow up adj (study or studies)).tw.	39447
67	(observational adj (study or studies)).tw.	51101
68	Longitudinal.tw.	156253
69	Retrospective.tw.	300619
70	Cross sectional.tw.	189832
71	Cross-sectional studies/	193365
72	or/60-71	2038085
73	30 and (or/59,72)	273
74	limit 73 to (danish or english or swedish or norwegian)	233
75	limit 74 to yr="2003 -Current"	100

PICO 3

ID	Søgeterm	Hits
1	rhinitis/	9320
2	rhinitis, allergic, perennial/	7522
3	rhinitis, allergic, seasonal/	12641
4	allergic rhinitis.mp.	13055
5	seasonal rhinitis.mp.	281
6	perennial rhinitis.mp.	517
7	rhinoconjunctivitis.mp.	1744
8	hay fever/	12641
9	Hay fever.mp.	3353
10	Hayfever.mp.	333
11	Nasal allerg*.mp.	1268
12	nasal obstruction/	3835
13	Nasal congestion.mp.	1509
14	nose congestion.mp.	4
15	congested nose.mp.	19
16	nose obstruction.mp.	22
17	nasal obstruction.mp.	6642
18	pruritus/	9136
19	nasal pruritus.mp.	49
20	Nasal itch*.mp.	234
21	itchy nose*.mp.	114
22	Rhinorrhoea.mp.	4878
23	or/1-22	50987
24	Leukotriene Antagonists/	2817
25	Antileukotrien*.mp.	342
26	Leukotrien*.mp.	21829
27	Montelukast.mp.	1925
28	or/24-27	22513
29	histamine antagonists/	4918
30	exp histamine H1 antagonists/	32888
31	Antihistamine.mp.	4203
32	Histamin* H1 antagonist*.mp.	15076
33	Acrivastin*.mp.	105
34	Bilastin*.mp.	49
35	Cetirizin*.mp.	1589
36	Desloratadin*.mp.	505
37	Ebastin*.mp.	283
38	Fexofanadin*.mp.	0
39	Levocetirizin*.mp.	319
40	Loratadin*.mp.	1365
41	or/29-40	38829

42	23 and 28 and 41	296
43	Randomized Controlled Trials as Topic/	101331
44	randomized controlled trial/	405785
45	Random Allocation/	84695
46	Double Blind Method/	133639
47	Single Blind Method/	20905
48	clinical trial/	503327
49	clinical trial, phase i.pt.	15622
50	clinical trial, phase ii.pt.	25012
51	clinical trial, phase iii.pt.	10287
52	clinical trial, phase iv.pt.	1063
53	controlled clinical trial.pt.	91153
54	randomized controlled trial.pt.	405785
55	multicenter study.pt.	192411
56	clinical trial.pt.	503327
57	exp Clinical Trials as topic/	297851
58	or/43-57	1104298
59	(clinical adj trial\$.tw.	239978
60	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	138598
61	placebos/	34205
62	placebo\$.tw.	171396
63	randomly allocated.tw.	18565
64	(allocated adj2 random\$.tw.	21261
65	or/59-64	458962
66	58 or 65	1267329
67	case report.tw.	218459
68	letter/	892720
69	historical article/	314933
70	or/67-69	1413800
71	66 not 70	1235870
72	42 and 71	144
73	limit 72 to (danish or english or swedish or norwegian)	133
74	limit 73 to yr="2007 -Current"	57

PICO 4

ID	Søgeterm	Hits
1	rhinitis/	9237
2	rhinitis, allergic, perennial/	7494
3	rhinitis, allergic, seasonal/	12586
4	allergic rhinitis.mp.	12902
5	seasonal rhinitis.mp.	279
6	perennial rhinitis.mp.	516
7	rhinoconjunctivitis.mp.	1723
8	hay fever/	12586
9	Hay fever.mp.	3342
10	Hayfever.mp.	332
11	Nasal allerg*.mp.	1263
12	nasal obstruction/	3805
13	Nasal congestion.mp.	1491
14	nose congestion.mp.	4
15	congested nose.mp.	19
16	nose obstruction.mp.	22
17	nasal obstruction.mp.	6580
18	pruritus/	9083
19	nasal pruritus.mp.	48
20	Nasal itch*.mp.	232
21	itchy nose*.mp.	113
22	Rhinorrhea.mp.	4841
23	or/1-22	50581
24	exp steroids/	724340
25	Steroid*.mp.	276651
26	exp corticosteroids/	346351
27	Corticosteroid*.mp.	79896
28	Glucocorticoid*.mp.	89305
29	Methylprednisolon*.mp.	21846
30	Hydrocortison*.mp.	68921
31	Triamcinolonhexacetonid*.mp.	5
32	or/24-31	985027
33	Injections, Intramuscular/	27697
34	Depot.mp.	9547
35	Intramuscular.mp.	51384
36	Prolonged.mp.	243275
37	Systemic.mp.	371516
38	or/33-37	660393
39	histamine antagonists/	4879
40	exp histamine H1 antagonists/	32792
41	Antihistamine.mp.	4162

42	Histamin* H1 antagonist*.mp.	15024
43	Acrivastin*.mp.	104
44	Bilastin*.mp.	48
45	Cetirizin*.mp.	1571
46	Desloratadin*.mp.	494
47	Ebastin*.mp.	272
48	Fexofanadin*.mp.	0
49	Levocetirizin*.mp.	313
50	Loratadin*.mp.	1341
51	or/39-50	38680
52	Nasal steroid*.mp.	377
53	Nasal glucocorticoid*.mp.	30
54	Beclomethason*.mp.	3569
55	Budesonid*.mp.	4901
56	Fluticason*.mp.	3549
57	Momethason*.mp.	9
58	Triamcinolon*.mp.	9951
59	Ciclesonid*.mp.	300
60	or/52-59	20566
61	and/23,32,38,51,60	44
62	Randomized Controlled Trials as Topic/	99741
63	randomized controlled trial/	400708
64	Random Allocation/	84147
65	Double Blind Method/	132583
66	Single Blind Method/	20647
67	clinical trial/	501512
68	clinical trial, phase i.pt.	15355
69	clinical trial, phase ii.pt.	24586
70	clinical trial, phase iii.pt.	10075
71	clinical trial, phase iv.pt.	1037
72	controlled clinical trial.pt.	90738
73	randomized controlled trial.pt.	400708
74	multicenter study.pt.	188835
75	clinical trial.pt.	501512
76	exp Clinical Trials as topic/	294927
77	or/62-76	1091507
78	(clinical adj trial\$.tw.	236170
79	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	137262
80	placebos/	34020
81	placebo\$.tw.	169541
82	randomly allocated.tw.	18317
83	(allocated adj2 random\$.tw.	20993
84	or/78-83	453201

85	77 or 84	1252407
86	case report.tw.	216451
87	letter/	886612
88	historical article/	312834
89	or/86-88	1403683
90	85 not 89	1221156
91	Epidemiologic studies/	6277
92	exp case control studies/	712375
93	exp cohort studies/	1441309
94	Case control.tw.	85453
95	(cohort adj (study or studies)).tw.	100075
96	Cohort analy\$.tw.	4222
97	(Follow up adj (study or studies)).tw.	39447
98	(observational adj (study or studies)).tw.	51101
99	Longitudinal.tw.	156253
100	Retrospective.tw.	300619
101	Cross sectional.tw.	189832
102	Cross-sectional studies/	193365
103	or/91-102	2038085
104	61 and (or/90,103)	31
105	limit 104 to (danish or english or swedish or norwegian)	30
106	limit 105 to yr="2003 -Current"	9

PICO 5

ID	Søgeterm	Hits
1	rhinitis/	9237
2	rhinitis, allergic, perennial/	7494
3	rhinitis, allergic, seasonal/	12586
4	allergic rhinitis.mp.	12902
5	seasonal rhinitis.mp.	279
6	perennial rhinitis.mp.	516
7	rhinoconjunctivitis.mp.	1723
8	hay fever/	12586
9	Hay fever.mp.	3342
10	Hayfever.mp.	332
11	Nasal allerg*.mp.	1263
12	nasal obstruction/	3805
13	Nasal congestion.mp.	1491
14	nose congestion.mp.	4
15	congested nose.mp.	19
16	nose obstruction.mp.	22
17	nasal obstruction.mp.	6580
18	pruritus/	9083
19	nasal pruritus.mp.	48
20	Nasal itch*.mp.	232
21	itchy nose*.mp.	113
22	Rhinorrhea.mp.	4841
23	or/1-22	50581
24	exp steroids/	724340
25	Steroid*.mp.	276651
26	exp corticosteroids/	346351
27	Corticosteroid*.mp.	79896
28	Glucocorticoid*.mp.	89305
29	Dexamethason*.mp.	60404
30	Prednison*.mp.	46466
31	Prednisolon*.mp.	39311
32	Methylprednisolon*.mp.	21846
33	Hydrocortison*.mp.	68921
34	Triamcinolonhexacetonid*.mp.	5
35	or/24-34	1005259
36	Injections, Intramuscular/	27697
37	Depot.mp.	9547
38	Intramuscular.mp.	51384
39	Prolonged.mp.	243275
40	Systemic.mp.	371516
41	or/36-40	660393

42	oral drug administration/	118056
43	oral*.mp.	578205
44	per os.mp.	4960
45	or/42-44	581616
46	and/23,35,41,45	215
47	Randomized Controlled Trials as Topic/	99741
48	randomized controlled trial/	400708
49	Random Allocation/	84147
50	Double Blind Method/	132583
51	Single Blind Method/	20647
52	clinical trial/	501512
53	clinical trial, phase i.pt.	15355
54	clinical trial, phase ii.pt.	24586
55	clinical trial, phase iii.pt.	10075
56	clinical trial, phase iv.pt.	1037
57	controlled clinical trial.pt.	90738
58	randomized controlled trial.pt.	400708
59	multicenter study.pt.	188835
60	clinical trial.pt.	501512
61	exp Clinical Trials as topic/	294927
62	or/47-61	1091507
63	(clinical adj trial\$.tw.	236170
64	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	137262
65	placebos/	34020
66	placebo\$.tw.	169541
67	randomly allocated.tw.	18317
68	(allocated adj2 random\$.tw.	20993
69	or/63-68	453201
70	62 or 69	1252407
71	case report.tw.	216451
72	letter/	886612
73	historical article/	312834
74	or/71-73	1403683
75	70 not 74	1221156
76	Epidemiologic studies/	6277
77	exp case control studies/	712375
78	exp cohort studies/	1441309
79	Case control.tw.	85453
80	(cohort adj (study or studies)).tw.	100075
81	Cohort analy\$.tw.	4222
82	(Follow up adj (study or studies)).tw.	39447
83	(observational adj (study or studies)).tw.	51101
84	Longitudinal.tw.	156253

85	Retrospective.tw.	300619
86	Cross sectional.tw.	189832
87	Cross-sectional studies/	193365
88	or/76-87	2038085
89	46 and (or/75,88)	113
90	limit 89 to (danish or english or swedish or norwegian)	107
91	limit 90 to yr="2003 -Current"	60

PICO 6+8

ID	Søgeterm	Hits
1	exp pollen/	15216
2	exp pollen allergy/	12641
3	pollen.mp.	24489
4	grass.mp.	16199
5	birch.mp.	3225
6	or/1-5	46898
7	rhinitis/	9320
8	rhinitis, allergic, perennial/	7522
9	rhinitis, allergic, seasonal/	12641
10	allergic rhinitis.mp.	13055
11	seasonal rhinitis.mp.	281
12	perennial rhinitis.mp.	517
13	rhinoconjunctivitis.mp.	1744
14	hay fever/	12641
15	Hay fever.mp.	3353
16	Hayfever.mp.	333
17	Nasal allerg*.mp.	1268
18	nasal obstruction/	3835
19	Nasal congestion.mp.	1509
20	nose congestion.mp.	4
21	congested nose.mp.	19
22	nose obstruction.mp.	22
23	nasal obstruction.mp.	6642
24	pruritus/	9136
25	nasal pruritus.mp.	49
26	Nasal itch*.mp.	234
27	itchy nose*.mp.	114
28	Rhinorrhea.mp.	4878
29	or/7-28	50987
30	exp immunotherapy/	220990
31	Immunotherapy.mp.	65628
32	Desensiti*.mp.	33506
33	Hyposensiti*.mp.	1917

34	or/30-33	266372
35	and/6,29,34	2938
36	Randomized Controlled Trials as Topic/	101331
37	randomized controlled trial/	405785
38	Random Allocation/	84695
39	Double Blind Method/	133639
40	Single Blind Method/	20905
41	clinical trial/	503327
42	clinical trial, phase i.pt.	15622
43	clinical trial, phase ii.pt.	25012
44	clinical trial, phase iii.pt.	10287
45	clinical trial, phase iv.pt.	1063
46	controlled clinical trial.pt.	91153
47	randomized controlled trial.pt.	405785
48	multicenter study.pt.	192411
49	clinical trial.pt.	503327
50	exp Clinical Trials as topic/	297851
51	or/36-50	1104298
52	(clinical adj trial\$).tw.	239978
53	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	138598
54	placebos/	34205
55	placebo\$.tw.	171396
56	randomly allocated.tw.	18565
57	(allocated adj2 random\$).tw.	21261
58	or/52-57	458962
59	51 or 58	1267329
60	case report.tw.	218459
61	letter/	892720
62	historical article/	314933
63	or/60-62	1413800
64	59 not 63	1235870
65	and/35,64	964
66	limit 65 to (danish or english or swedish or norwegian)	866
67	limit 66 to yr="2009 -Current"	278

PICO 7

ID	Søgeterm	Hits
1	rhinitis/	9320
2	rhinitis, allergic, perennial/	7522
3	rhinitis, allergic, seasonal/	12641
4	allergic rhinitis.mp.	13055
5	seasonal rhinitis.mp.	281
6	perennial rhinitis.mp.	517
7	rhinoconjunctivitis.mp.	1744
8	hay fever/	12641
9	Hay fever.mp.	3353
10	Hayfever.mp.	333
11	Nasal allerg*.mp.	1268
12	nasal obstruction/	3835
13	Nasal congestion.mp.	1509
14	nose congestion.mp.	4
15	congested nose.mp.	19
16	nose obstruction.mp.	22
17	nasal obstruction.mp.	6642
18	pruritus/	9136
19	nasal pruritus.mp.	49
20	Nasal itch*.mp.	234
21	itchy nose*.mp.	114
22	Rhinorrhea.mp.	4878
23	or/1-22	50987
24	exp immunotherapy/	220990
25	Immunotherapy.mp.	65628
26	Desensiti*.mp.	33506
27	Hyposensiti*.mp.	1917
28	or/24-27	266372
29	exp mites/	12755
30	house dust.mp.	6676
31	mite*.mp.	19564
32	exp dermatophagoides/	1870
33	dermatophagoid*.mp.	4971
34	or/29-33	22577
35	and/23,28,34	715
36	Randomized Controlled Trials as Topic/	101331
37	randomized controlled trial/	405785
38	Random Allocation/	84695
39	Double Blind Method/	133639
40	Single Blind Method/	20905
41	clinical trial/	503327

42	clinical trial, phase i.pt.	15622
43	clinical trial, phase ii.pt.	25012
44	clinical trial, phase iii.pt.	10287
45	clinical trial, phase iv.pt.	1063
46	controlled clinical trial.pt.	91153
47	randomized controlled trial.pt.	405785
48	multicenter study.pt.	192411
49	clinical trial.pt.	503327
50	exp Clinical Trials as topic/	297851
51	or/36-50	1104298
52	(clinical adj trial\$.tw.	239978
53	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	138598
54	placebos/	34205
55	placebo\$.tw.	171396
56	randomly allocated.tw.	18565
57	(allocated adj2 random\$.tw.	21261
58	or/52-57	458962
59	51 or 58	1267329
60	case report.tw.	218459
61	letter/	892720
62	historical article/	314933
63	or/60-62	1413800
64	59 not 63	1235870
65	35 and 64	278
66	limit 65 to (danish or english or swedish or norwegian)	232
67	limit 66 to yr="2009 -Current"	78
68	limit 66 to yr="2007-2008"	21

PICO 9.1

ID	Søgeterm	Hits
1	cleaning/	6542
2	Cleaning*.mp.	25192
3	vacuum*.mp.	29067
4	Ventilat*.mp.	222241
5	Chemical*.mp.	1243857
6	Matress*.mp.	41
7	Filter*.mp.	132574
8	Air-filter*.mp.	1000
9	Carpet*.mp.	2607
10	Wash*.mp.	125099
11	or/1-10	1736826
12	allergic rhinitis/	20568
13	Allergic rhinitis.mp.	26394
14	Allergic rhinoconjunctivis.mp.	1
15	rhinoconjunctivitis/	3225
16	hay fever/	9182
17	Hay fever.mp.	9925
18	Hayfever.mp.	437
19	Nasal allergy.mp.	1096
20	Nasal allergies.mp.	166
21	nose obstruction/	8230
22	Nasal congestion.mp.	2300
23	nose congestion.mp.	5192
24	congested nose.mp.	23
25	nose obstruction.mp.	8248
26	nasal obstruction.mp.	5404
27	nasal pruritus/	701
28	nasal pruritus.mp.	734
29	Nasal itch*.mp.	397
30	itchy nose*.mp.	202
31	rhinorrhea/	6488
32	Rhinorrhea.mp.	9761
33	or/12-32	55188
34	exp mite/	18444
35	exp mite infestation/	6925
36	house dust allergy/	1719
37	house dust allergen/	4391
38	house dust.mp.	12287
39	mite*.mp.	22540
40	exp dermatophagoides/	7220
41	dermatophagoid*.mp.	8673

42	or/34-41	32822
43	and/11,33,42	189
44	meta analysis/	84746
45	"meta analysis (topic)"/	16069
46	systemat*.ti,ot,ab. and review.pt.	63360
47	meta analys*.ti,ot,kw.	50994
48	metaanalys*.ti,ot,kw.	1664
49	systematic review*.ti,ot,kw.	47978
50	"cochrane database of systematic reviews".jn.	3780
51	or/44-50	177302
52	and/43,51	8
53	limit 52 to (danish or english or swedish or norwegian)	6
54	limit 53 to yr="2003 -Current"	5

PICO 9.2

ID	Søgeterm	Hits
1	Rhinitis, Allergic, Perennial/	7509
2	RHINITIS/ or RHINITI*.tw.	26431
3	ALLERG*.tw.	148729
4	2 and 3	17001
5	1 or 4	18988
6	MITES/	9286
7	ALLERGENS/	33092
8	ANTIGENS/	62819
9	ANTIGENS,DERMATOPHAGOIDES/	2513
10	DUST/	17994
11	"Air Pollution, Indoor"/	9885
12	(MITE* or DUST* or HDM or PYROGLYPHIDAEOREUROGLYPHUS or DERMATOPHAGOIDES or BLOMIA TROPICALIS or NORISEN or PHARMALGEN).tw.	42044
13	or/6-12	145452
14	5 and 13	4982
15	PRIMARY PREVENTION/	14823
16	"Bedding and Linens"/ or "Floors and Floorcoverings"/ or "Environmental Exposure"/ or "Environmental Exposure/pre-vention and control"/	64570
17	(MITE* and (PROOF or IMPERMEABLE or REDUC* or ELIMINAT* or DESTROY* or EXTERMINAT* or ERADICAT* or REMOV* or KILL* or SPRAY*)).tw.	3048
18	(CEDAR or ACARICID* or ACARACID*OR NEEM OIL or NEEMOIL or MARGOSA or MITICIDE).tw.	3582
19	(BENZYL BENZOATE or BENZYLbenzoate or BIOMAL or MILBIOL or NEEMOL or SPINNRAD or TN MP 100 or TNMP100 or NIMBASAN).tw.	369
20	(DWELLING* or HOUSE* or UPHOLSTER* or PILLOW* or MATTRESS* or BED or BEDS or BEDDING or CUSHION* or COVER* or ENCAS* or SOFT FURNISHING* or CARPET* or FLOOR* or CURTAIN).tw.	500433

21	or/15-20	577379
22	14 and 21	1741
23	limit 22 to (danish or english or swedish or norwegian)	1411
24	limit 23 to yr="2009 -Current"	387
25	Randomized Controlled Trials as Topic/	100107
26	randomized controlled trial/	401556
27	Random Allocation/	84222
28	Double Blind Method/	132775
29	Single Blind Method/	20696
30	clinical trial/	501894
31	clinical trial, phase i.pt.	15392
32	clinical trial, phase ii.pt.	24644
33	clinical trial, phase iii.pt.	10102
34	clinical trial, phase iv.pt.	1040
35	controlled clinical trial.pt.	90822
36	randomized controlled trial.pt.	401556
37	multicenter study.pt.	189367
38	clinical trial.pt.	501894
39	exp Clinical Trials as topic/	295658
40	or/25-39	1093765
41	(clinical adj trial\$).tw.	237734
42	((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	137824
43	placebos/	34060
44	placebo\$.tw.	170301
45	randomly allocated.tw.	18409
46	(allocated adj2 random\$).tw.	21093
47	or/41-46	455544
48	40 or 47	1256216
49	case report.tw.	217164
50	letter/	889394
51	historical article/	313126
52	or/49-51	1407428
53	48 not 52	1224925
54	24 and 53	90